mage-a3 asci
Vaccineexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2011 (NCT01245673)
Timeline
Indications
Mechanism of action
- Melanoma-associated antigen 3Immunity, active
MAGEA3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mage-a3 asci
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01498172 | Phase 1 | Jan 1, 2012 | GlaxoSmithKline, Ludwig Institute for Cancer Research, University of Lausanne |
| NCT01437605 | Phase 2 | Oct 11, 2011 | GlaxoSmithKline, Oncovir, Inc., University of South Florida |
| NCT01245673 | Phase 2 | Apr 1, 2011 | University of Maryland, University of Pennsylvania |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 0 | 2 | 2011 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2011 |
| University of Lausanne | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2011 |
7 organizations
Page 1 / 1